Product Information
TRI-VYLIBRA LO TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.1083 per EA under NDC 50102023113. Its NADAC has been published 381 times since May 8, 2019.
FDA first approved this application on Nov 4, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Afaxys Pharma, LLCNDC
50102023113
Classification
Generic
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205762FDA Approved
11/4/2016
TE Code
AB
On Market Since
11/4/2016
Price Statistics
The NADAC for TRI-VYLIBRA LO TABLET has been published 381 times since May 8, 2019, and over the history we have for it it has declined 48.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1083 per EA |
|---|---|
| All-time high | $0.2607 (Jun 12, 2019) |
| All-time low | $0.0903 (Nov 20, 2024) |
| 52-week high | $0.1148 |
| 52-week low | $0.1046 |
| Median price | $0.1606 |
| Average price | $0.1573 |
| Largest weekly change | -27.8% (Apr 17, 2024) |
| Weeks tracked | 381 |
| Tracking since | May 8, 2019 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRI-VYLIBRA LO TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-VYLIBRA LO TABLET, manufactured by Afaxys Pharma, LLC, is $0.1083 per EA (NDC 50102023113), effective Aug 19, 2026.
How has the price of TRI-VYLIBRA LO TABLET changed over time?
Over the history we have for it, the NADAC for TRI-VYLIBRA LO TABLET has declined 48.7%. It has been tracked across 381 weekly CMS publications since May 8, 2019.
What are the highest and lowest recorded NADAC prices for TRI-VYLIBRA LO TABLET?
Since May 8, 2019, the NADAC for TRI-VYLIBRA LO TABLET has ranged from a low of $0.0903 (Nov 20, 2024) to a high of $0.2607 (Jun 12, 2019), with a median of $0.1606 per EA.
Are there cheaper alternatives to TRI-VYLIBRA LO TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TRI-VYLIBRA LO TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TRI-VYLIBRA LO TABLET?
TRI-VYLIBRA LO TABLET (NDC 50102023113) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.